Fineotex Chemical Limited

Basic Materials — Specialty Chemicals · NSE

₹57.05−₹0.85 (−1.47%)

DalalBaazaar Score

52 / 100

🟡 Moderate

Verdict

CAUTION

Risk

Moderate

Driven by moderate debt load, negative free cash flow, small-cap size, which brings sharper price swings.

In simple words: Strong business and financial position, with both sales and profits growing well. Cash generation is currently the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 6:59 pm

Understanding the Business

Company site ↗

The 60-second version of Fineotex Chemical Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Fineotex Chemical Limited manufactures and sells textile chemicals, auxiliaries, and specialty chemicals in India, Malaysia, and the United States.

IndustrySpecialty Chemicals

SectorBasic Materials

Employees214

Annual revenue₹771 Cr

How does it make money?

Turns over ₹771 Cr a year. Of every ₹100 of sales, about ₹14 reaches shareholders as profit, with ₹20 left at the operating level before interest, tax and depreciation. Each of its 214 employees supports ₹3.60 Cr of revenue a year, the signature of a capital- or asset-led business.

Revenue / employee₹3.60 Cr

Who are its competitors?

The closest listed comparisons in its industry are ASIAN PAINTS LIMITED, PIDILITE INDUSTRIES LTD, SRF LTD, UPL LIMITED. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Some evidence

ROCE of 16.1% is above what capital typically costs, which suggests some pricing power, though not yet the sustained, wide gap that marks a durable advantage.

Peer median ROE22.3%

What is the outlook?

1 analysts covering the stock expect revenue to grow about 21.8% and earnings to grow about 40.0% in the year to 2028. These are estimates by people who follow the company, not a forecast for the wider industry.

Est. revenue growth+21.8%

Est. earnings growth+40.0%

Analysts1

What has been driving growth?

Growth has come mainly from selling more, rather than from keeping more of each sale. Over 3 years revenue moved +49% while net margin moved -18% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+49%

Margin effect-18%

DalalBaazaar Score

52/ 100

Moderate

Weighted across six categories. Every point is explained below.

✗ P/E of 44.6x is demanding — it needs sustained high growth to justify
✗ P/E is 839% above its own historical median of 4.7x — expensive by its own standards
✗ P/B of 5.38x is a steep premium to book

Quality vs. Valuation

Company Quality

57/ 100

Average

How good the business is, ignoring the share price entirely.

Valuation

31/ 100

Expensive

What you are being asked to pay, ignoring how good the business is.

A reasonable business at a reasonable price — neither the quality nor the valuation stands out in either direction.

Historical Valuation

Current P/E

44.6x

3Y Median

4.7x

40 monthly readings · mean 16.9x · range 2.1x–60.8x

Sector Median

40.4x

median of 4 sector peers

⚠️Current valuation is approximately 839% above its 3y median of 4.7x. Paying more than usual needs a reason — faster growth, a better balance sheet, or a re-rating you believe in.

🟡Against its sector it is priced broadly in line with the peer median of 40.4x.

vs. its own history

Expensive

4.7x median over 40 months · +839%

vs. sector peers

Fair

40.4x median of 4 peers · +10%

vs. generic bands

Expensive

Above 35x

EV/EBITDA

43.6x

PEG

6.20

What's Good / What's Bad

🟢 What's Going Well1

Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention2

Return on equity is falling
ROE has dropped from 25.3% to 12.3% — each rupee of shareholder capital earns less than it did.
Return on capital is falling
ROCE has declined from 32.0% to 16.1% — often a sign of competition or overexpansion.

Red Flags

6 items require attention · 3 high · 3 watch

🔴Profit up while operating cash flow fallsFinancial
Reported profit rose but cash generated by operations declined — worth checking whether earnings are being supported by non-cash items or working capital.
🔴Receivables growing faster than salesFinancial
Receivables up 186% against revenue up 49% — sales are being booked faster than they are collected.
🔴Inventory building faster than salesFinancial
Inventory up 227% against revenue up 49% — stock may not be moving.
🟡Free cash flow is negativeFinancial
Free cash flow was -₹48 Cr in the latest year.
🟡Margins are compressingFinancial
EBITDA margin is down 2.8 points over 3 years.
🟡Shareholders have been dilutedOwnership
Shares outstanding are up 951% over 3 years — each existing share owns a smaller slice of the company.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

Margins are being competed away
EBITDA margin has fallen from 22.5% to 19.7%. If the trend continues, profit falls even on flat sales — and margin decline rarely reverses quickly.
Sales are being booked faster than collected
Receivables are up 186% against revenue up 49%. If customers keep taking longer to pay, reported profit will not turn into cash — and write-offs follow if some never do.
The price already assumes success
The stock trades 839% above its own median multiple. At this level the business has to deliver just to stand still, and a stumble is repriced twice — lower earnings on a lower multiple.
Returns on shareholder capital are falling
ROE has dropped from 25.3% to 12.3%. Each rupee of equity earns less than it did, so profit growth increasingly depends on raising more capital rather than on the existing base working harder.
Size brings its own risk
Small Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Revenue growth stays above 11% a year✓ 14.3% CAGR
Latest reported year was 174.8%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
2EBITDA margin holds above 18%✓ 19.7%
Two points below today's level — enough room for noise, tight enough to catch real compression.
3Free cash flow remains positive✗ -₹48 Cr
Profit that never becomes cash eventually stops being profit.
4Debt / EBITDA stays below 2x✓ 0.1x
The ratio lenders write covenants against; it survives a small or negative equity base, unlike Debt/Equity.
5ROCE stays above 13%✓ 16.1%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

9 / 12 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✓ Strong return on capital employed (ROCE ≥ 15%)
✓ Healthy net margin (≥ 10%)
✗ Generates positive free cash flow
✓ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✗ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✓ Analyst consensus isn't majority-sell
✓ Short-term technical trend isn't bearish

Price history

Quick Metrics

4 good · 4 neutral · 3 weak

Market Cap

₹6,643 Cr

Small Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

44.6x

Expensive

Expensive — verify against sector peers

P/B Ratio

5.38x

Rich

Steep premium to book — needs high, durable returns to justify

EPS (TTM)

₹1.28

Profitable

Profitable on a per-share basis

ROE

12.3%

Moderate

Moderate capital efficiency

ROCE

16.1%

Strong

Earns comfortably above its likely cost of capital

Debt/Equity

0.87x

Moderate

Moderate leverage

Revenue Growth (YoY)

174.8%

Healthy

Healthy top-line growth

Profit Growth (YoY)

88.1%

Healthy

Profits growing at a healthy clip

Dividend Yield

0.23%

Modest

Small cash return — most of the return has to come from the price

Free Cash Flow

-₹48 Cr

Cash burning

Spending more cash than the operations bring in

More Metrics

P/E (Forward)

27.2x

Improving

Below the trailing multiple — the street expects earnings to grow into the price

Operating Margin

14.5%

Average

Average margins

Net Margin

12.1%

Good

Strong bottom-line conversion

Current Ratio

2.80

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

0.73

Defensive

Steadier than the market

52W Range Position

88%

Near high

Near its 52-week high

Technical Snapshot

SMA 20 / SMA 50

57.3 / 52.2

Bullish alignment (short > long)

Price vs SMA 200

Above

Long-term uptrend

RSI (14)

43.6

Neutral momentum

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹516 Cr	₹568 Cr	₹532 Cr	₹771 Cr	+14.3%
EBITDA	₹116 Cr	₹151 Cr	₹132 Cr	₹152 Cr	+9.4%
EBITDA Margin	22.5%	26.6%	24.8%	19.7%	—
PAT (Net Profit)	₹88 Cr	₹120 Cr	₹108 Cr	₹109 Cr	+7.2%
EPS	₹7.97	₹10.82	₹0.95	₹0.94	-50.9%
ROE	25.3%	26.8%	14.8%	12.3%	—
ROCE	32.0%	34.4%	18.9%	16.1%	—
Total Debt	₹7 Cr	₹5 Cr	₹0 Cr	₹8 Cr	+4.0%
Free Cash Flow	₹88 Cr	₹49 Cr	₹2 Cr	-₹48 Cr	—

🟢 Revenue has grown at 14.3% a year over 3 years.

🟢 EBITDA has grown at 9.4% a year over 3 years.

🔴 EBITDA Margin has fallen from 22.5% to 19.7% over 3 years (-2.8 pts).

🟢 PAT (Net Profit) has grown at 7.2% a year over 3 years.

🔴 EPS has shrunk at 50.9% a year over 3 years.

🔴 ROE has fallen from 25.3% to 12.3% over 3 years (-13.0 pts).

🔴 ROCE has fallen from 32.0% to 16.1% over 3 years (-15.9 pts).

🔴 Total Debt has grown at 4.0% a year over 3 years.

🔴 Free Cash Flow has turned negative, from ₹88 Cr to -₹48 Cr.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹1,159 Cr

Total Liabilities

₹219 Cr

Cash & Equivalents

₹37 Cr

Operating Cash Flow

-₹24 Cr

Capex

-₹25 Cr

Shareholding (proxy)

Institutional Holding

2.2%

Insider Holding

65.6%

Corporate Actions

Dividend Rate

₹0.13

Ex-Dividend Date

04 Sept 2026

Analyst Consensus

Recommendations

2 Buy · 0 Hold · 0 Sell

Target Price (Mean)

₹39.5

-30.8% vs CMP

Target Range

₹28 – ₹51

Peer Comparison

Company	P/E	ROE
ASIAN PAINTS LIMITED	46.9x	22.3%
PIDILITE INDUSTRIES LTD	57.8x	24.4%
SRF LTD	33.8x	15.4%
UPL LIMITED	21.5x	6.1%

Recent News

1 mixed5 general

FCL Forecast — Price Target — Prediction for 2027

TradingView, 23 JulAnalyst view

🟡Mixed / dependsBroker commentary — an opinion about the price rather than new information about the business.

Fineotex Chemical Share Price News: Valuation and Peers

Univest, 25 Sept

Compare FINEOTEX CHEMICAL with

Equitymaster, 17 Oct

Fineotex Chemical targets USD 100 million from US ops in FY27

scanx.trade, 23 Jul

Buy Fineotex Chemical; target of Rs 51: Choice Institutional Equities

Moneycontrol.com, 22 Jul

Fineotex Chemical - FIIs bet on high-growth smallcaps: 14 stocks rally up to 225% in 5 months, 6 turn multibaggers

The Economic Times, 01 Jun

Watch Items

Cross-check against the company's latest quarterly filing / investor presentation before acting.

DalalBaazaar Thesis

StrongFinancial Health

MiddlingBusiness Quality · Growth · Profitability · Risk

WeakValuation

Points for each in the Score ↑

Unremarkable in both directions

A reasonable business at a reasonable price. Nothing here is alarming and nothing is compelling, which usually means the decision rests on things this data cannot see — the industry's direction, management's intent, and what else is available to you. 3 high-severity red flags sit above this conclusion and should be read first.

1 of 5 tripwires tripped — Free cash flow remains positive · see Key things to watch ↑